No Data
No Data
Analysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)
Palisade Bio, Inc.'s Success on the Line: The Critical Role of Retaining Top Talent Without Safeguards
Palisade Bio GAAP EPS of -$1.80 Misses by $0.85, Revenue of $0.25M
Palisade Bio Q4 EPS $(0.25) Beats $(0.34) Estimate
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.34) by 26.47 percent. This is a 98.45 percent increase over losses of $(16.16
Palisade Bio FY23 Loss/Shr $1.80 >PALI
Palisade Bio FY23 Loss/Shr $1.80 >PALI
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
– Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end– Formation of Clinical Advisory
No Data